Figure 2.
Cardiovascular and metabolic disease-related contexts with increased GRK2 levels and effects of interfering GRK2 expression or functionality. Enhanced GRK2 levels have been reported in different tissues and cell types of patients and/or preclinical models of the indicated situations associated with cardiovascular and metabolic diseases. On the other hand, interfering GRK2 functionality in these settings in preclinical models can modulate different relevant cellular processes implicated in disease development and progression. See text for details.